Alzheimer's Biomarkers Gain Prominence In Drug Development Guidance
Executive Summary
US FDA revises draft guidance issued in 2013 to allow research targeting cognition as single endpoint and studies solely evaluating biomarkers; document offers 'potential for multiple advances,' Alzheimer's Association says.
You may also be interested in...
Alzheimer’s And Surrogate Endpoints: FDA’s On A Case-By-Case Basis Per New Guidance
After Aduhelm and Leqembi rendered the 2018 guidance moot, FDA formally acknowledges the possibility of using surrogate endpoints for accelerated approval in Alzheimer’s in updated draft but says acceptability of the any endpoint will depend on details of specific therapeutic program.
Eisai/Biogen Remain In BACE Race As Alzheimer's Contenders Dwindle
Multiple competitors have ended development of BACE inhibitors for the treatment of Alzheimer's disease, but Eisai neurology executive Lynn Kramer tells Scrip that the company still sees a path forward for certain amyloid-targeting drugs.
Pharmas Join To Build Inflammation Biomarkers In Alzheimer's, Depression
Drug firms exploring link between inflammation and central nervous system disorders are now sharing resources through public/private Biomarkers Consortium project.